- About us
- Join Putnam
Explore our latest insights and perspectives in these life science resources, news articles, and events.
Putnam PHMR’s client needed a detailed description of multiple myeloma treatment patterns and resource utilization in Japanese patients...
An emerging biotech sought Putnam’s guidance to design and execute the global commercialization of their asset for a rare oncology indication.
A global, top-10 pharma client sought Putnam’s guidance on developing a lean launch strategy for a novel cell therapy in oncology.
The client with a focus on developing pipeline asset for KRAS G12C segment sought granular insights for competitive edge in treatment sequencing.
Putnam PHMAR helped the client to support development of local medical launch readiness plans for a new vaccine.
A company was approaching the European market with evidence from a placebo-controlled RCT, but with several established competitors...
With several other in-class competitors, a client sought Putnam’s guidance on a go/no-go development decision for a first-generation targeted...
A clinical-stage biopharmaceutical company sought to develop an optimized portfolio strategy. It sought Putnam’s guidance to prioritize asset-level...
Stay ahead in vaccine market strategy as competitor's halt forces Putnam's client to adapt global forecasts for dynamic launch scenarios.
Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment...
Read how our client aims to locate organizations advancing AI algorithms for rare disease detection.